PA550963
FSHR Polyclonal Antibody, Invitrogen™
Manufacturer: Thermo Scientific
Select a Size
| Pack Size | SKU | Availability | Price |
|---|---|---|---|
| Each of 1 | PA550963-Each-of-1 | In Stock | ₹ 46,324.50 |
PA550963 - Each of 1
In Stock
Quantity
1
Base Price: ₹ 46,324.50
GST (18%): ₹ 8,338.41
Total Price: ₹ 54,662.91
Antigen
FSHR
Classification
Polyclonal
Conjugate
Unconjugated
Gene
FSHR
Gene Alias
follicle stimulating hormone receptor; follicle-stimulating hormone receptor; Follitropin receptor; FSH receptor; Fshr; FSH-R; FSHR1; FSHRO; LGR1; ODG1
Host Species
Rabbit
Purification Method
Antigen affinity chromatography
Regulatory Status
RUO
Gene ID (Entrez)
14309, 2492, 25449
Content And Storage
-20° C, Avoid Freeze/Thaw Cycles
Form
Liquid
Applications
ELISA, Immunocytochemistry, Immunohistochemistry, Western Blot
Concentration
1 mg/mL
Formulation
PBS with 0.5% BSA, 50% glycerol and 0.02% sodium azide; pH 7.4
Gene Accession No.
P20395, P23945, P35378
Gene Symbols
FSHR
Immunogen
Synthesized peptide derived from the Internal region of human FSHR.
Quantity
100 μL
Primary or Secondary
Primary
Target Species
Human, Mouse, Rat
Product Type
Antibody
Isotype
IgG
Related Products
Description
- FSH Receptor / FSHR Polyclonal Antibody detects endogenous levels of FSH Receptor / FSHR protein
- Follicle-Stimulating Hormone Receptor (FSHR) expression has been reported in ovary, uterus, and testis
- ESTs have been isolated from testis libraries
- G-protein Coupled Receptors (GPCRs) comprise one of the largest families of signaling molecules with more than a thousand members currently predicted to exist
- All GPCRs share a structural motif consisting of seven membrane-spanning helices, and exist in both active and inactive forms
- An array of activating ligands participate in the conformation of GPCRs which leads to signaling via G-proteins and downstream effectors
- Ongoing studies have also shown the vast series of reactions which participate in the negative regulation of GPCRs
- This turn-off activity has tremendous implications for the physiological action of the cell, and continues to drive pharmacological research for new drug candidates
- Two blockbuster drugs which have been developed as GPCR-targeted pharmaceuticals are Zyprexa (Eli Lilly) and Claritin (Schering-Plough) which have multi-billion dollar shares of the mental health and allergy markets, respectively.